Decreased placental and muscular expression of the fibroblast growth factor 19 in gestational diabetes mellitus

Wang, Dongyu; Xu, Shuqia; Ding, Wenjiang; Zhu, Cairong; Deng, Shan; Qiu, Xiwen; Wang, Zilian

doi:10.1111/jdi.12859

Cited by 16 publications

(20 citation statements)

References 28 publications

(47 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, in a recent study of 45 subjects in whom FGF21 levels were measured at the time of elective caesarean section, maternal serum FGF21 levels were comparable between GDM patients and controls. 28 Together, all these studies showing comparable circulating FGF21 levels in pregnant women with and without GDM were not consistent with the beneficial effects of FGF21 on glucose metabolism found in animal studies. 13,18 The main reason for these discrepant results may be that all of these studies were very small and the results may simply be a reflection of chance findings.…”

Section: Studies That Failed To Find a Difference In Circulating Fgmentioning

confidence: 71%

“…Despite the positive findings from the study of Nitert et al,15 data on FGF21 expression in the placenta are discordant. In a recent study by Wang et al,28 no significant differences were found between GDM women and controls in regard to FGF21 mRNA and protein levels in the placenta. This difference could be partly explained by the different diagnostic criteria of GDM between the two studies, resulting in the fact that glycaemic levels of subjects in the Wang et al study were significantly higher than those in the Nitert et al study.…”

mentioning

confidence: 79%

“…15,21,[23][24][25][26][27][28] This review aims to synthesize data from original research on FGF21 levels in patients with GDM in order to guide future research directions and to explore the therapeutic potential of FGF21 in GDM. 15,21,[23][24][25][26][27][28] This review aims to synthesize data from original research on FGF21 levels in patients with GDM in order to guide future research directions and to explore the therapeutic potential of FGF21 in GDM.…”

Section: Introductionmentioning

confidence: 99%

“…There are a limited number of studies investigating circulating levels of FGF21 in patients with GDM compared to those without. 15,21,[23][24][25][26][27][28] This review aims to synthesize data from original research on FGF21 levels in patients with GDM in order to guide future research directions and to explore the therapeutic potential of FGF21 in GDM.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Role of fibroblast growth factor 21 in gestational diabetes mellitus: A mini‐review

Yuan

Henry

et al. 2018

Clinical Endocrinology

View full text Add to dashboard Cite

Gestational diabetes mellitus (GDM) is defined as glucose intolerance with onset or first diagnosis during pregnancy, but not to the level of being diagnostic for diabetes in a nonpregnant adult. 1 During pregnancy, maternal tissues become progressively insensitive to insulin due to metabolic changes that ensure adequate nutrition is supplied to the foetus. 2,3 One such change is that insulin-mediated whole-body glucose disposal decreases by 40%-60%, necessitating a 200%-250% increase in insulin secretion in order to maintain a normal blood glucose concentration. 4 GDM develops when a pregnant woman does not produce enough insulin to compensate for this insulin resistance. 2 GDM is a serious, common complication in pregnancy, threatening the health of one in every 7 pregnant women globally, their foetuses and newborns. 5-8 It increases the risk of maternal hypertensive disorders of pregnancy, foetal macrosomia, caesarean section, traumatic injury at birth for both mother and baby and other adverse pregnancy outcomes. 6,7,9 Moreover, GDM is also associated Abstract Gestational diabetes mellitus (GDM) is defined as glucose intolerance with onset or first diagnosis during pregnancy, but not to the level of being diagnostic for diabetes in a nonpregnant adult. In GDM, whole-body insulin-dependent glucose disposal decreases by 40%-60% which necessitates a 200%-250% increase in insulin secretion to maintain normoglycaemia. GDM develops when a pregnant woman does not produce sufficient insulin to compensate for the reduced glucose disposal. Fibroblast

show abstract

Section: Studies That Failed To Find a Difference In Circulating Fgmentioning

confidence: 71%

mentioning

confidence: 79%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Role of fibroblast growth factor 21 in gestational diabetes mellitus: A mini‐review

Yuan

Henry

et al. 2018

Clinical Endocrinology

View full text Add to dashboard Cite

show abstract

“…Downregulation of FGF19 may be associated with the status of sarcopenia in the UC patient group, since 66.7%(26/39) of them had muscle invasive diseases. Furthermore, diabetes and low visceral fat condition may also be associated with lower FGF19 level in previous studies [20,21]. All above reasons could be the possible confounding factors of FGF19 downregulation in UC patients.…”

Section: Discussionmentioning

confidence: 84%

Alteration in serum concentrations of FGF19, FGF21, and FGF23 in patients with urothelial carcinoma

Chiu

et al. 2018

BioFactors

View full text Add to dashboard Cite

Fibroblast growth factors (FGF) 19, 21, and 23 have been reported as functional factors in human metabolic diseases and malignancies. We performed a prospective survey to compare circulating FGF levels in urothelial carcinoma (UC) patients and normal controls. Between 2016 and 2017, 39 patients with UC of the urinary bladder or upper urinary tract who received surgical intervention were included. All the serum samples were obtained before surgeries. The control group included 28 healthy volunteers. Analysis of the circulating FGF19, 21, and 23 levels among all 67 subjects, as well as a subgroup analysis of the 39 UC patients were performed. The median levels of serum FGF19, 21, and 23 in the UC patients were 84.2, 505.3, and 117.6 pg/mL, respectively, which were statistically different from levels found in the healthy controls (P = 0.015, <0.001 and < 0.001, respectively). In the subgroup analysis, the FGF19 and FGF21 levels were significantly higher in end‐stage renal disease UC patients, while FGF21 was also higher in the UC patients with cardiovascular diseases and history of recurrent UC. In the receiver operating characteristic (ROC) curve analysis, FGF19, 21, and 23 were all significant predictors of UC [area under the curve (AUC)] 0.674, P = 0.015; AUC 0.918, P < 0.001; AUC 0.897, P < 0.001, respectively). In UC patients, serum FGF19 level was significantly lower, while FGF21 and 23 were significantly higher, than respective levels in healthy controls. All three markers may serve as good predictors of UC occurrence, and FGF21 level was associated with disease recurrence. © 2018 BioFactors, 45(1):62–68, 2019

show abstract

Diagnosis of pregnancy disorder in the first‐trimester patient plasma with Raman spectroscopy and protein analysis

Mathew,

Cutshaw,

Appel

et al. 2024

Bioengineering & Transla Med

View full text Add to dashboard Cite

Gestational diabetes mellitus (GDM) is a pregnancy disorder associated with short‐ and long‐term adverse outcomes in both mothers and infants. The current clinical test of blood glucose levels late in the second trimester is inadequate for early detection of GDM. Here we show the utility of Raman spectroscopy (RS) for rapid and highly sensitive maternal metabolome screening for GDM in the first trimester. Key metabolites, including phospholipids, carbohydrates, and major amino acids, were identified with RS and validated with mass spectrometry, enabling insights into associated metabolic pathway enrichment. Using classical machine learning (ML) approaches, we showed the performance of the RS metabolic model (cross‐validation AUC 0.97) surpassed that achieved with patients' clinical data alone (cross‐validation AUC 0.59) or prior studies with single biomarkers. Further, we analyzed novel proteins and identified fetuin‐A as a promising candidate for early GDM prediction. A correlation analysis showed a moderate to strong correlation between multiple metabolites and proteins, suggesting a combined protein‐metabolic analysis integrated with ML would enable a powerful screening platform for first trimester diagnosis. Our study underscores RS metabolic profiling as a cost‐effective tool that can be integrated into the current clinical workflow for accurate risk stratification of GDM and to improve both maternal and neonatal outcomes.

show abstract

Decreased placental and muscular expression of the fibroblast growth factor 19 in gestational diabetes mellitus

Cited by 16 publications

References 28 publications

Role of fibroblast growth factor 21 in gestational diabetes mellitus: A mini‐review

Role of fibroblast growth factor 21 in gestational diabetes mellitus: A mini‐review

Alteration in serum concentrations of FGF19, FGF21, and FGF23 in patients with urothelial carcinoma

Diagnosis of pregnancy disorder in the first‐trimester patient plasma with Raman spectroscopy and protein analysis

Contact Info

Product

Resources

About